Safety and utility of image-guided research biopsies in relapsed high-grade serous ovarian carcinoma—experience of the BriTROC consortium

Goranova, T. et al. (2017) Safety and utility of image-guided research biopsies in relapsed high-grade serous ovarian carcinoma—experience of the BriTROC consortium. British Journal of Cancer, 116, pp. 1294-1301. (doi:10.1038/bjc.2017.86) (PMID:28359078)

[img]
Preview
Text
137785.pdf - Published Version
Available under License Creative Commons Attribution Non-commercial Share Alike.

581kB
[img]
Preview
Text
137785Suppl.pdf - Supplemental Material

861kB

Abstract

Background: Investigating tumour evolution and acquired chemotherapy resistance requires analysis of sequential tumour material. We describe the feasibility of obtaining research biopsies in women with relapsed ovarian high-grade serous carcinoma (HGSC). Methods: Women with relapsed ovarian HGSC underwent either image-guided biopsy or intra-operative biopsy during secondary debulking, and samples were fixed in methanol-based fixative. Tagged-amplicon sequencing was performed on biopsy DNA. Results: We screened 519 patients in order to enrol 220. Two hundred and two patients underwent successful biopsy, 118 of which were image-guided. There were 22 study-related adverse events (AE) in the image-guided biopsies, all grades 1 and 2; pain was the commonest AE. There were pre-specified significant AE in 3/118 biopsies (2.5%). 87% biopsies were fit-for-purpose for genomic analyses. Median DNA yield was 2.87 mg, and was higher in biopsies utilising 14 G or 16 G needles compared to 18 G. TP53 mutations were identified in 94.4% patients. Conclusions: Obtaining tumour biopsies for research in relapsed HGSC is safe and feasible. Adverse events are rare. The large majority of biopsies yield sufficient DNA for genomic analyses—we recommend use of larger gauge needles and methanol fixation for such biopsies, as DNA yields are higher but with no increase in AEs.

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Paul, Mr James and Ennis, Dr Darren and Wilson, Ms Cheryl and Lewsley, Ms Liz-Anne and Stobo, Mr Jon and Mcneish, Professor Iain and Glasspool, Dr Rosalind
Authors: Goranova, T., Ennis, D., Piskorz, A. M., Macintyre, G., Lewsley, L.-A., Stobo, J., Wilson, C., Kay, D., Glasspool, R. M., Lockley, M., Brockbank, E., Montes, A., Walther, A., Sundar, S., Edmondson, R., Hall, G. D., Clamp, A., Gourley, C., Hall, M., Fotopoulou, C., Gabra, H., Freeman, S., Moore, L., Jimenez-Linan, M., Paul, J., Brenton, J. D., and McNeish, I. A.
College/School:College of Medical Veterinary and Life Sciences > Institute of Cancer Sciences
College of Medical Veterinary and Life Sciences > School of Medicine, Dentistry & Nursing
Journal Name:British Journal of Cancer
Publisher:Nature Publishing Group
ISSN:0007-0920
ISSN (Online):1532-1827
Published Online:30 March 2017
Copyright Holders:Copyright © 2017 The Authors
First Published:First published in British Journal of Cancer 116:1294–1301
Publisher Policy:Reproduced under a Creative Commons License

University Staff: Request a correction | Enlighten Editors: Update this record

Project CodeAward NoProject NamePrincipal InvestigatorFunder's NameFunder RefLead Dept
643981Personalised biomarkers of response in high-grade serious ovarian cancerIain McNeishCancer Research UK (CAN-RES-UK)C608/A15973RI CANCER SCIENCES